Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Fang J"" wg kryterium: Autor


Wyświetlanie 1-20 z 20
Tytuł:
Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma.
Autorzy:
Chen W; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Liao Y; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Sun P; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Tu J; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Zou Y; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Fang J; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Chen Z; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Li H; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Chen J; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Peng Y; Macau University of Science and Technology, Macau, 999078, China.
Wen L; Department of Anesthesiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. .
Xie X; Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China. .; Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Jan 16; Vol. 22 (1), pp. 66. Date of Electronic Publication: 2024 Jan 16.
Typ publikacji:
Journal Article
MeSH Terms:
Osteosarcoma*/drug therapy
Osteosarcoma*/genetics
Antineoplastic Agents*
Bone Neoplasms*/drug therapy
Bone Neoplasms*/genetics
Protein Disulfide Reductase (Glutathione)*
Adolescent ; Animals ; Humans ; Prognosis ; Algorithms
Czasopismo naukowe
Tytuł:
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.
Autorzy:
Wei Q; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China.
Li P; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.; Department of Radiation Oncology, Zhejiang Cancer Hospital, Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Hangzhou, China.
Yang T; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Zhu J; Zhejiang Chinese Medical University, Hangzhou, China.
Sun L; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.; Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Zhang Z; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Wang L; Department of Radiation Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
Tian X; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.; Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Shanghai, China.; College of Molecular Medicine, Hangzhou Institute for Advanced Study (HIAS), University of Chinese Academy of Sciences, Hangzhou, China.
Chen J; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China.; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
Hu C; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China.; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
Xue J; Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Ma L; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Shimura T; Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Fang J; School of Life Science and Technology, Tongji University, Shanghai, China.
Ying J; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. .; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. .; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China. .
Guo P; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. .; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China. .
Cheng X; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. .; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China. .; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2024 Jan 04; Vol. 17 (1), pp. 1. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunoconjugates*/therapeutic use
Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; Immunotherapy
Czasopismo naukowe
Tytuł:
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
Autorzy:
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Zhou J; Department of Respiratory Medicine, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Zhao Y; Department of Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Zhu B; Department of Oncology, Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Zhang L; Department of Medical Oncology, Yantai Yuhuangding Hospital, Yantai, China.
Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fang J; Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China.
Shi J; Department of Medical Oncology, Linyi Cancer Hospital, Linyi, China.
Zhuang Z; Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Yang S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Wang D; Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Yu H; Department of Palliative Care, Department of Geriatric Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Zhang L; Department of Radiotherapy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zheng R; Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Greco M; Department of Drug Discovery, Beta Pharma Inc., Princeton, NJ, USA.
Wang T; Department of Clinical Development, Beta Pharma (Shanghai) Co., Ltd, Shanghai, China.
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2023 Jan 08; Vol. 21 (1), pp. 11. Date of Electronic Publication: 2023 Jan 08.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Antineoplastic Agents*/adverse effects
Humans ; Protein Kinase Inhibitors/adverse effects ; ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Mutation
Czasopismo naukowe
Tytuł:
Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology.
Autorzy:
Wang H; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
He Y; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Jian M; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Fu X; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Cheng Y; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
He Y; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Fang J; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Li L; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Zhang D; Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.; Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Nov 02; Vol. 27 (21). Date of Electronic Publication: 2022 Nov 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Biological Products*/pharmacology
Biological Products*/therapeutic use
Biological Products*/chemistry
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Neoplasms*/drug therapy
Humans ; Synthetic Biology ; Fungi
Czasopismo naukowe
Tytuł:
In vitro and in vivo evaluation of self-assembled chitosan nanoparticles selectively overcoming hepatocellular carcinoma via asialoglycoprotein receptor.
Autorzy:
Sun R; Collage of Pharmacy, Dalian Medical University, Dalian, China.
Fang L; Collage of Pharmacy, Dalian Medical University, Dalian, China.
Lv X; Collage of Integrative Medicine, Dalian Medical University, Dalian, China.
Fang J; Collage of Pharmacy, Dalian Medical University, Dalian, China.
Wang Y; Collage of Pharmacy, Dalian Medical University, Dalian, China.
Chen D; Laboratory Animal Center, Dalian Medical University, Dalian, China.
Wang L; Laboratory Animal Center, Dalian Medical University, Dalian, China.
Chen J; Laboratory Animal Center, Dalian Medical University, Dalian, China.
Qi Y; Collage of Pharmacy, Dalian Medical University, Dalian, China.
Tang Z; Collage of Pharmacy, Dalian Medical University, Dalian, China.
Zhang J; Collage of Pharmacy, Dalian Medical University, Dalian, China.
Tian Y; Collage of Pharmacy, Dalian Medical University, Dalian, China.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 2071-2084.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*pharmacology
Asialoglycoprotein Receptor/*drug effects
Carcinoma, Hepatocellular/*pathology
Doxorubicin/*pharmacology
Liver Neoplasms/*pathology
Nanoparticles/*chemistry
Animals ; Antineoplastic Agents/administration & dosage ; Cell Movement/drug effects ; Cell Survival/drug effects ; Chemistry, Pharmaceutical ; Chitosan/chemistry ; Doxorubicin/administration & dosage ; Drug Carriers/chemistry ; Drug Liberation ; Hep G2 Cells ; Humans ; Hydrophobic and Hydrophilic Interactions ; Male ; Mice ; Mice, Inbred BALB C ; Random Allocation ; Spectroscopy, Fourier Transform Infrared ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
Quinonoids: Therapeutic Potential for Lung Cancer Treatment.
Autorzy:
Ying HZ; Key Laboratory of Experimental Animal and Safety Evaluation, Hangzhou Medical College, Hangzhou 310013, China.
Yu CH; Key Laboratory of Experimental Animal and Safety Evaluation, Hangzhou Medical College, Hangzhou 310013, China.
Chen HK; Key Laboratory of Experimental Animal and Safety Evaluation, Hangzhou Medical College, Hangzhou 310013, China.
Zhang HH; Key Laboratory of Experimental Animal and Safety Evaluation, Hangzhou Medical College, Hangzhou 310013, China.
Fang J; Key Laboratory of Experimental Animal and Safety Evaluation, Hangzhou Medical College, Hangzhou 310013, China.
Wu F; Key Laboratory of Experimental Animal and Safety Evaluation, Hangzhou Medical College, Hangzhou 310013, China.
Yu WY; Key Laboratory of Experimental Animal and Safety Evaluation, Hangzhou Medical College, Hangzhou 310013, China.; Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Institute of Materia Medica, Hangzhou Medical College, Hangzhou 310013, China.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2020 Apr 06; Vol. 2020, pp. 2460565. Date of Electronic Publication: 2020 Apr 06 (Print Publication: 2020).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents/*pharmacology
Antineoplastic Agents/*therapeutic use
Lung Neoplasms/*drug therapy
Quinones/*pharmacology
Quinones/*therapeutic use
Animals ; Apoptosis/drug effects ; Autophagy/drug effects ; Biological Products/pharmacology ; Biological Products/therapeutic use ; Humans ; Neovascularization, Pathologic/drug therapy
Czasopismo naukowe
Tytuł:
Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
Autorzy:
Wu D; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Liang L; Department of Tumor Chemotherapy and Radiation Sickness, Third Hospital, Peking University, Beijing, China.
Nie L; Department of Pulmonary and Critical Care Medicine, Peking University First Hospital, Beijing, China.
Nie J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Dai L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Hu W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Zhang J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Chen X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Han J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Ma X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Tian G; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Han S; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Long J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Wang Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Zhang Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Xin T; Department of Medical Oncology, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.
Fang J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
Pokaż więcej
Źródło:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2018 Dec; Vol. 14 (6), pp. 446-452. Date of Electronic Publication: 2018 Mar 24.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Salvage Therapy*
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Pyridines/*therapeutic use
Aged ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Safety ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł:
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.
Autorzy:
Zhong Q; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.; Beijing Institute of Otolaryngology, Beijing, China.; Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China.
Fang J; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China. .; Beijing Institute of Otolaryngology, Beijing, China. .; Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China. .
Huang Z; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.; Beijing Institute of Otolaryngology, Beijing, China.; Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China.
Yang Y; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.; Beijing Institute of Otolaryngology, Beijing, China.; Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China.
Lian M; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.; Beijing Institute of Otolaryngology, Beijing, China.; Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China.
Liu H; Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, 100730, China.
Zhang Y; Department of Urology, The Second Affiliated Hospital of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Ye J; Neurontechnology, Shenzhen, Guangdong, China.
Hui X; Department of Cell Biology and Medical Genetics, Shenzhen University Medical School, Shenzhen, 518060, China.
Wang Y; Department of Cell Biology and Medical Genetics, Shenzhen University Medical School, Shenzhen, 518060, China.
Ying Y; Department of Physiology, School of Basic Medical Sciences, Shenzhen University Health Sciences Center, Shenzhen, 518060, China.
Zhang Q; Neurontechnology, Shenzhen, Guangdong, China. .
Cheng Y; Department of Urology, The Second Affiliated Hospital of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2018 Aug 23; Vol. 8 (1), pp. 12675. Date of Electronic Publication: 2018 Aug 23.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Bridged-Ring Compounds/*therapeutic use
Cisplatin/*therapeutic use
Fluorouracil/*therapeutic use
Head and Neck Neoplasms/*drug therapy
Hypopharyngeal Neoplasms/*drug therapy
Taxoids/*therapeutic use
Adult ; Aged ; Female ; Humans ; In Vitro Techniques ; Male ; Middle Aged ; Support Vector Machine
Czasopismo naukowe
Tytuł:
In vivo gene expression profiling for chemosensitivity to docetaxel-cisplatin-5-FU (TPF) triplet regimen in laryngeal squamous cell carcinoma and the effect of TPF treatment on related gene expression in vitro.
Autorzy:
Lian M; a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren Hospital, Capital Medical University , Beijing , PR China.
Shi Q; a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren Hospital, Capital Medical University , Beijing , PR China.
Fang J; a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren Hospital, Capital Medical University , Beijing , PR China.
Feng L; a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren Hospital, Capital Medical University , Beijing , PR China.
Ma H; a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren Hospital, Capital Medical University , Beijing , PR China.
Wang H; a Department of Otorhinolaryngology Head and Neck Surgery , Beijing Tongren Hospital, Capital Medical University , Beijing , PR China.
Zhang L; b Key Laboratory of Otorhinolaryngology Head and Neck Surgery, Ministry of Education , Beijing Institute of Otorhinolaryngology , Beijing , PR China.
Wang H; b Key Laboratory of Otorhinolaryngology Head and Neck Surgery, Ministry of Education , Beijing Institute of Otorhinolaryngology , Beijing , PR China.
Ma Z; c Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology , Beijing , PR China.
Liu H; c Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology , Beijing , PR China.
Pokaż więcej
Źródło:
Acta oto-laryngologica [Acta Otolaryngol] 2017 Jul; Vol. 137 (7), pp. 765-772. Date of Electronic Publication: 2017 Jan 26.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*
Antineoplastic Combined Chemotherapy Protocols*
Drug Resistance, Neoplasm*
Carcinoma, Squamous Cell/*metabolism
Laryngeal Neoplasms/*metabolism
Aged ; Carcinoma, Squamous Cell/drug therapy ; Case-Control Studies ; Cell Line, Tumor ; Female ; Gene Expression Profiling ; Humans ; Laryngeal Neoplasms/drug therapy ; Male ; Middle Aged ; Wnt Signaling Pathway
Czasopismo naukowe
Tytuł:
Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity.
Autorzy:
Wang W; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Shao A; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Zhang N; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Fang J; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Ruan JJ; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Ruan BH; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2017 Feb 22; Vol. 7, pp. 43036. Date of Electronic Publication: 2017 Feb 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Doxorubicin/*chemistry
Liposomes/*chemistry
Polymethacrylic Acids/*chemistry
Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/metabolism ; Antineoplastic Agents/therapeutic use ; Cations/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Doxorubicin/metabolism ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Drug Liberation ; Humans ; Mice ; Mice, Inbred ICR ; Nanoparticles/chemistry ; Neoplasms/drug therapy ; Neoplasms/pathology ; Particle Size
Czasopismo naukowe
Tytuł:
Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma.
Autorzy:
Dai J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.
Wu S; College of Engineering, Peking University, Beijing, 100871, China.; Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Kong Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.
Chi Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.
Si L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.
Sheng X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.
Cui C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.
Fang J; College of Engineering, Peking University, Beijing, 100871, China.; Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Zhang J; College of Engineering, Peking University, Beijing, 100871, China.; Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2017 Jan 05; Vol. 7, pp. 39597. Date of Electronic Publication: 2017 Jan 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Electric Stimulation Therapy/*methods
Everolimus/*administration & dosage
Melanoma/*therapy
Skin Neoplasms/*therapy
TOR Serine-Threonine Kinases/*antagonists & inhibitors
Animals ; Apoptosis ; Cell Line, Tumor ; Combined Modality Therapy ; Female ; Humans ; Melanoma/complications ; Melanoma, Experimental/complications ; Melanoma, Experimental/therapy ; Mice, Inbred BALB C ; Neovascularization, Pathologic/complications ; Time Factors
Czasopismo naukowe
Tytuł:
Inferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic properties.
Autorzy:
Wang Y; Key Laboratory of Adaptation and Evolution of Plateau Biota, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining, 810001 China.
Fang J; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD 20850, USA.
Chen S; Key Laboratory of Adaptation and Evolution of Plateau Biota, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining, 810001 China.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2016 Sep 20; Vol. 6, pp. 32679. Date of Electronic Publication: 2016 Sep 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Genomics*
Antineoplastic Agents/*therapeutic use
Neoplasms/*drug therapy
Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Humans ; Inhibitory Concentration 50 ; Neoplasms/pathology ; Organ Specificity ; ROC Curve
Czasopismo naukowe
Tytuł:
A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
Autorzy:
Maeda H; Institute of Drug Delivery Science, Sojo University, Kumamoto, Japan.
Tsukigawa K; Institute of Drug Delivery Science, Sojo University, Kumamoto, Japan.
Fang J; Institute of Drug Delivery Science, Sojo University, Kumamoto, Japan.
Pokaż więcej
Źródło:
Microcirculation (New York, N.Y. : 1994) [Microcirculation] 2016 Apr; Vol. 23 (3), pp. 173-82.
Typ publikacji:
Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Neoplasms*/blood
Neoplasms*/pathology
Neoplasms*/therapy
Neovascularization, Pathologic*/metabolism
Neovascularization, Pathologic*/pathology
Neovascularization, Pathologic*/therapy
Antineoplastic Agents/*therapeutic use
Drug Delivery Systems/*methods
Photochemotherapy/*methods
Antineoplastic Agents/history ; Drug Delivery Systems/history ; History, 20th Century ; History, 21st Century ; Neoplasm Metastasis ; Permeability ; Photochemotherapy/history
Czasopismo naukowe
Tytuł:
Styrene-maleic acid-copolymer conjugated zinc protoporphyrin as a candidate drug for tumor-targeted therapy and imaging.
Autorzy:
Fang J; a Research Institute of Drug Delivery Sciences .; b Faculty of Pharmaceutical Science , and.
Tsukigawa K; a Research Institute of Drug Delivery Sciences .; b Faculty of Pharmaceutical Science , and.
Liao L; a Research Institute of Drug Delivery Sciences .; c Department of Applied Microbiology , Sojo University , Kumamoto , Japan.
Yin H; a Research Institute of Drug Delivery Sciences .
Eguchi K; b Faculty of Pharmaceutical Science , and.
Maeda H; a Research Institute of Drug Delivery Sciences .
Pokaż więcej
Źródło:
Journal of drug targeting [J Drug Target] 2016; Vol. 24 (5), pp. 399-407. Date of Electronic Publication: 2015 Aug 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Maleates/*pharmacology
Metalloporphyrins/*pharmacology
Polystyrenes/*pharmacology
Protoporphyrins/*pharmacology
Styrene/*pharmacology
Animals ; Cell Line, Tumor ; Drug Delivery Systems/methods ; Female ; HeLa Cells ; Heme Oxygenase-1/metabolism ; Humans ; Male ; Mice ; Micelles ; Particle Size ; Permeability ; Photochemotherapy/methods ; Solubility ; Uterine Cervical Neoplasms/drug therapy
Czasopismo naukowe
Tytuł:
3,4,4'-Trihydroxy-trans-stilbene, an analogue of resveratrol, is a potent antioxidant and cytotoxic agent.
Autorzy:
Cai W; State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, Gansu, China.
Zhang L
Song Y
Zhang B
Cui X
Hu G
Fang J
Pokaż więcej
Źródło:
Free radical research [Free Radic Res] 2011 Nov; Vol. 45 (11-12), pp. 1379-87. Date of Electronic Publication: 2011 Oct 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Antioxidants/*pharmacology
Stilbenes/*chemistry
Stilbenes/*pharmacology
Anisoles/chemistry ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Antioxidants/chemical synthesis ; Antioxidants/chemistry ; Cell Proliferation/drug effects ; DNA Damage/drug effects ; Free Radicals/chemistry ; HL-60 Cells/drug effects ; Hemolysis/drug effects ; Humans ; Kinetics ; Linoleic Acid/chemistry ; Lipid Peroxidation/drug effects ; Molecular Structure ; Oxidative Stress/drug effects ; Resveratrol ; Stilbenes/chemical synthesis ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł:
Tumor-targeted induction of oxystress for cancer therapy.
Autorzy:
Fang J; Laboratory of Microbiology and Oncology, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan. />Nakamura H
Iyer AK
Pokaż więcej
Źródło:
Journal of drug targeting [J Drug Target] 2007 Aug-Sep; Vol. 15 (7-8), pp. 475-86.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Drug Delivery Systems*
Antineoplastic Agents/*pharmacology
Neoplasms/*drug therapy
Reactive Oxygen Species/*metabolism
Animals ; Apoptosis/drug effects ; Drug Design ; Heme Oxygenase-1/antagonists & inhibitors ; Heme Oxygenase-1/metabolism ; Humans ; Neoplasms/physiopathology ; Oxidation-Reduction ; Permeability
Czasopismo naukowe
Tytuł:
miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.
Autorzy:
Su, S-F
Chang, Y-W
Andreu-Vieyra, C
Fang, J Y
Yang, Z
Han, B
Lee, A S
Liang, G
Pokaż więcej
Temat:
MICRORNA
ENDOPLASMIC reticulum
MOLECULAR chaperones
GENETIC regulation
CELLULAR signal transduction
ANTINEOPLASTIC agents
Źródło:
Oncogene; 9/26/2013, Vol. 32 Issue 39, p4694-4701, 8p
Czasopismo naukowe
Tytuł:
Effect of trans-retinoic acid and folic acid on apoptosis in human gastric cancer cell lines MKN-45 and MKN-28.
Autorzy:
Fang, Jing-Yuan
Xiao, Shu-Dong
Fang, J Y
Xiao, S D
Pokaż więcej
Temat:
APOPTOSIS
TRETINOIN
STOMACH cancer
FOLIC acid
PHYSIOLOGY
AGAR
ANTINEOPLASTIC agents
COMPARATIVE studies
ELECTROPHORESIS
GENETIC techniques
HEMATOPOIETIC agents
RESEARCH methodology
MEDICAL cooperation
RESEARCH
STOMACH tumors
EVALUATION research
CANCER cell culture
PHARMACODYNAMICS
Źródło:
Journal of Gastroenterology; 1998, Vol. 33 Issue 5, p656-661, 6p
Czasopismo naukowe
    Wyświetlanie 1-20 z 20

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies